H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. The company has strong momentum heading into 2025 with its long-term guidance raised, the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz
- Halozyme raises FY25 adjusted EPS view to $4.95-$5.35 from $4.45-$4.85
- Halozyme announces new $250M accelerated share repurchase plan
- Halozyme backs FY24 adjusted EPS view $4.00-$4.20, consensus $4.14
- Halozyme announces Takeda receives approval for HYQVIA by MHLW